Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2016

Open Access 01-12-2016 | Research article

The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries

Authors: A. Lewis, S. Torvinen, P. N. R. Dekhuijzen, H. Chrystyn, A. T. Watson, M. Blackney, A. Plich

Published in: BMC Health Services Research | Issue 1/2016

Login to get access

Abstract

Background

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic inflammatory respiratory diseases, which impose a substantial burden on healthcare systems and society. Fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA), often administered using dry powder inhalers (DPIs), are frequently prescribed to control persistent asthma and COPD. Use of DPIs has been associated with poor inhalation technique, which can lead to increased healthcare resource use and costs.

Methods

A model was developed to estimate the healthcare resource use and costs associated with asthma and COPD management in people using commonly prescribed DPIs (budesonide + formoterol Turbuhaler® or fluticasone + salmeterol Accuhaler®) over 1 year in Spain, Sweden and the United Kingdom (UK). The model considered direct costs (inhaler acquisition costs and scheduled and unscheduled healthcare costs), indirect costs (productive days lost), and estimated the contribution of poor inhalation technique to the burden of illness.

Results

The direct cost burden of managing asthma and COPD for people using budesonide + formoterol Turbuhaler® or fluticasone + salmeterol Accuhaler® in 2015 was estimated at €813 million, €560 million, and €774 million for Spain, Sweden and the UK, respectively. Poor inhalation technique comprised 2.2–7.7 % of direct costs, totalling €105 million across the three countries. When lost productivity costs were included, total expenditure increased to €1.4 billion, €1.7 billion and €3.3 billion in Spain, Sweden and the UK, respectively, with €782 million attributable to poor inhalation technique across the three countries. Sensitivity analyses showed that the model results were most sensitive to changes in the proportion of patients prescribed ICS and LABA FDCs, and least sensitive to differences in the number of antimicrobials and oral corticosteroids prescribed.

Conclusions

The cost of managing asthma and COPD using commonly prescribed DPIs is considerable. A substantial, and avoidable, contributor to this burden is poor inhalation technique. Measures that can improve inhalation technique with current DPIs, such as easier-to-use inhalers or better patient training, could offer benefits to patients and healthcare providers through improving disease outcomes and lowering costs.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Gonzalez-Barcala FJ et al. Factors associated with health-related quality of life in adults with asthma. A cross-sectional study. Multidiscip Respir Med. 2012;7(1):32.CrossRefPubMedPubMedCentral
4.
Apfelbacher CJ et al. Validity of two common asthma-specific quality of life questionnaires: juniper mini asthma quality of life questionnaire and Sydney asthma quality of life questionnaire. Health Qual Life Outcomes. 2012;10:97.CrossRefPubMedPubMedCentral
5.
6.
7.
8.
9.
10.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015. Global strategy for diagnosis, management, and prevention of COPD. Available from: http://​goldcopd.​org/​. Accessed: Mar 2015.
11.
Newman SP. Inhaler treatment options in COPD. Eur Resp Rev. 2005;14(96):102–8.CrossRef
12.
13.
Molimard M et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16(3):249–54.CrossRefPubMed
14.
Roche N et al. Effectiveness of inhaler devices in adult asthma and COPD. EMJ Respir. 2013;1:64–71.
15.
Laube BL et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–31.CrossRefPubMed
16.
17.
Dekhuijzen PNR et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respir Med. 2013;107(12):1817–21.CrossRefPubMed
18.
Broeders ME et al. The ADMIT series-issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J. 2009;18(2):76–82.CrossRefPubMed
19.
Melani AS et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–8.CrossRefPubMed
20.
Lavorini F et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593–604.CrossRefPubMed
21.
22.
Osman A et al. Are Sudanese community pharmacists capable to prescribe and demonstrate asthma inhaler devices to patrons? A mystery patient study. Pharm Pract (Granada). 2012;10(2):110–5.CrossRef
23.
Kim SH et al. Inappropriate techniques used by internal medicine residents with three kinds of inhalers (a metered dose inhaler, Diskus, and Turbuhaler): changes after a single teaching session. J Asthma. 2009;46(9):944–50.CrossRefPubMed
24.
Basheti IA et al. User error with Diskus and Turbuhaler by asthma patients and pharmacists in Jordan and Australia. Respir Care. 2011;56(12):1916–23.CrossRefPubMed
25.
Lenney J et al. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med. 2000;94(5):496–500.CrossRefPubMed
26.
Self TH et al. Inadequate skill of healthcare professionals in using asthma inhalation devices. J Asthma. 2007;44(8):593–8.CrossRefPubMed
27.
Crane MA et al. Inhaler device technique can be improved in older adults through tailored education: findings from a randomised controlled trial. NPJ Prim Care Respir Med. 2014;24:14034.PubMedPubMedCentral
28.
Newman S. Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery. Expert Opin Drug Deliv. 2014;11(3):365–78.CrossRefPubMed
29.
Price D et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013;107(1):37–46.CrossRefPubMed
30.
IMS Midas, MAT 06/’14. Data on file. TEVA Pharmaceuticals, Inc. Dec 2014
31.
32.
33.
34.
35.
36.
37.
38.
39.
Plaza V et al. GEMA (guía española de manejo del asma). Arch Bronconeumol. 2009;45(7):2–35.
40.
Ancochea J. Infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres cuantificación del problema, determinantes y propuestas de acción. Arch Bronconeumol. 2013;49(6):223–9.CrossRefPubMed
41.
42.
43.
44.
Covvey J et al. Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapy. Prim Care Respir J. 2013;22(3):209–5.
45.
46.
47.
48.
Martinez-Moragon E et al. Economic cost of treating the patient with asthma in Spain: the AsmaCost study. Arch Bronconeumol. 2009;45(10):481–6.CrossRefPubMed
49.
de Miguel DJ et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008;3(4):701–12.PubMedCentral
50.
51.
Basheti IA et al. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol. 2007;119(6):1537–8.CrossRefPubMed
52.
Toumas-Shehata M et al. Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallel-group, repeated-measures study. NPJ Prim Care Respir Med. 2014;24:14071.PubMedPubMedCentral
53.
Basheti IA et al. Inhaler technique training and health-care professionals: effective long-term solution for a current problem. Respir Care. 2014;59(11):1716–25.CrossRefPubMed
54.
Virchow JC et al. A review of the value of innovation in inhalers for COPD and asthma. JMAHP. 2015;3:28760.
55.
Small M et al. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;28:202–12.CrossRefPubMed
56.
Bender B, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol. 2004;4:191–5.CrossRefPubMed
57.
Panek M et al. The epidemiology of asthma and its comorbidities in Poland – health problems of patients with severe asthma as evidenced in the Province of Lodz. Respir Med. 2016;112:31–8.CrossRefPubMed
58.
59.
60.
Masa J et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol. 2004;40(2):72–9.CrossRefPubMed
61.
Orden 731/2013, de 6 de septiembre, del Consejero de Sanidad, por la que se fijan los precios públicos por la prestación de los servicios y actividades de naturaleza sanitaria de la Red de Centros de la Comunidad de Madrid.
62.
Jansson S et al. The economic consequences of asthma among adults in Sweden. Respir Med. 2007;101(11):2263–70.CrossRefPubMed
63.
64.
65.
66.
67.
68.
Martínez-Moragón E et al. Coste economico del paciente asmatico en España (Estudio AsmaCost). Arch Bronconeumol. 2009;45(10):481–6.CrossRefPubMed
69.
Erickson S et al. The impact of allergy and pulmonary specialist care on emergency asthma utilization in a large managed care organization. Health Serv Res. 2005;40(5):1443–65.CrossRefPubMedPubMedCentral
70.
Jansson SA et al. Health economic costs of COPD in Sweden by disease severity – has it changed during a ten years period? Respir Med. 2013;107(12):1931–8.CrossRefPubMed
71.
COPD Uncovered. Healthcare utilization in COPD: the burden carried by primary care. 5th ed. Toronto: IPCRG World Conference; 2010.
72.
73.
74.
75.
Accordini S et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol. 2013;160:93–101.CrossRefPubMed
76.
Forum. Clinical Review. Gauging the need for nurse-led clinics. May 2010.
77.
78.
79.
80.
Johnston S et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med. 2006;354(15):589–600.CrossRef
81.
Cole S et al. ‘The blue one takes a battering’ why do young adults with asthma overuse bronchodilator inhalers? A qualitative study. BMJ. 2013;3(2):e002247.CrossRef
82.
83.
Boggon R et al. Variability of antibiotic prescribing in patients with chronic obstructive pulmonary disease exacerbations: a cohort study. BMC Pulm Med. 2013;13:32.CrossRefPubMedPubMedCentral
84.
85.
86.
Ojeda P et al. Coste Asma Study. Costs associated with workdays lost and utilization of health care resources because of asthma in daily clinical practice in Spain. J Investig Allergol Clin Immunol. 2013;23(4):234–41.PubMed
87.
88.
89.
90.
Demoly P et al. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66–74.
91.
92.
Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006;3(7):619–23.CrossRefPubMed
Metadata
Title
The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries
Authors
A. Lewis
S. Torvinen
P. N. R. Dekhuijzen
H. Chrystyn
A. T. Watson
M. Blackney
A. Plich
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2016
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-016-1482-7

Other articles of this Issue 1/2016

BMC Health Services Research 1/2016 Go to the issue

Research article

A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems

Research article

The Quality of Working Life Questionnaire for Cancer Survivors (QWLQ-CS): a Pre-test Study

Research article

Help-seeking for mental health problems by employees in the Australian Mining Industry

Research article

The evolution of the health system outcomes in Central and Eastern Europe and their association with social, economic and political factors: an analysis of 25 years of transition

Research article

Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario

Study protocol

Outcome after polytrauma in a certified trauma network: comparing standard vs. maximum care facilities concept of the study and study protocol (POLYQUALY)